| Rituximab is successful first-line biologic for RA.(Across Specialties): An article from: Skin & Allergy News | Digitalby Nancy Walsh (Author)
| List Price: | $9.95 | | | Available: | Available for download now |
| | Binding: | Digital | | Publisher: | International Medical News Group | | Page Count: | 3 Pages | | Publication Date: | August 01, 2008 |
|
EDITORIAL REVIEWS |
Product Description
This digital document is an article from Skin & Allergy News, published by International Medical News Group on August 1, 2008. The length of the article is 814 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available immediately after purchase. You can view it with any web browser.Citation DetailsTitle: Rituximab is successful first-line biologic for RA.(Across Specialties)Author: Nancy WalshPublication: Skin & Allergy News (Magazine/Journal)Date: August 1, 2008Publisher: International Medical News GroupVolume: 39 Issue: 8 Page: 57(1)Distributed by Gale, a part of Cengage Learning |
|
